. "0002-9440" . "Modulation of the E2F1-Driven Cancer Cell Fate by the DNA Damage Response Machinery and Potential Novel E2F1 Targets in Osteosarcomas"@en . "17"^^ . . . "RIV/61989592:15110/09:00009728!RIV10-MSM-15110___" . "Tsangaris, George Th." . "Ginsberg,, Doron" . . "Evangelou, Konstantinos" . . . . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "Kotsinas,, Athanassios" . "16"^^ . . . "2"^^ . "B\u00E1rtek, Ji\u0159\u00ED" . "Zoumpourlis, Vassilis" . "[4E637385D441]" . "Modulation of the E2F1-Driven Cancer Cell Fate by the DNA Damage Response Machinery and Potential Novel E2F1 Targets in Osteosarcomas" . "15110" . "Osteosarcoma is the most common primary bone cancer. Mutations of the RB gene represent the most frequent molecular defect in this malignancy. A major consequence of this alteration is that the activity of the key cell cycle regulator E2F1 is unleashed from the inhibitory effects of pRb. Studies in animal models and in human cancers have shown that deregulated E2F1 overexpression possesses either ?oncogenic? or ?oncosuppressor? properties, depending on the cellular context. To address this issue in osteosarcomas, we examined the status of E2F1 relative to cell proliferation and apoptosis in a clinical setting of human primary osteosarcomas and in E2F1-inducible osteosarcoma cell line models that are wild-type and deficient for p53. Collectively, our data demonstrated that high E2F1 levels exerted a growth-suppressing effect that relied on the integrity of the DNA damage response network. Surprisingly, induction of p73, an established E2F1 target, was also DNA damage response- dependent. Furthermore, a"@en . "327186" . . . "1" . . "S, Z(MSM6198959216)" . "Halazonetis, Thanos D." . "Gorgoulis, Vassilis G." . . . "American Journal of Pathology" . "Niforou, Katerina" . "Apostolopoulou, Kalliopi" . "Damalas, Alexandros" . "Kittas, Christos" . "Modulation of the E2F1-Driven Cancer Cell Fate by the DNA Damage Response Machinery and Potential Novel E2F1 Targets in Osteosarcomas" . . "Liontos, Michalis" . . "Modulation of the E2F1-Driven Cancer Cell Fate by the DNA Damage Response Machinery and Potential Novel E2F1 Targets in Osteosarcomas"@en . "Vrt\u011Bl, Radek" . "Vougas, Konstantinos" . "RIV/61989592:15110/09:00009728" . . "175" . "Osteosarcoma is the most common primary bone cancer. Mutations of the RB gene represent the most frequent molecular defect in this malignancy. A major consequence of this alteration is that the activity of the key cell cycle regulator E2F1 is unleashed from the inhibitory effects of pRb. Studies in animal models and in human cancers have shown that deregulated E2F1 overexpression possesses either ?oncogenic? or ?oncosuppressor? properties, depending on the cellular context. To address this issue in osteosarcomas, we examined the status of E2F1 relative to cell proliferation and apoptosis in a clinical setting of human primary osteosarcomas and in E2F1-inducible osteosarcoma cell line models that are wild-type and deficient for p53. Collectively, our data demonstrated that high E2F1 levels exerted a growth-suppressing effect that relied on the integrity of the DNA damage response network. Surprisingly, induction of p73, an established E2F1 target, was also DNA damage response- dependent. Furthermore, a" . "Osteosarcoma; RB gene; DNA damage"@en . "Kontovazenitis, Panayiotis" . "Velimezi, Georgia" .